Latest News and Press Releases
Want to stay updated on the latest news?
-
This transaction completes Onxeo’s strategic transition to a company solely focused on DNA Damage Response (DDR) activities in oncology$6.6m received from Acrotech extends Onxeo’s cash runway into Q2...
-
PARIS, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
-
PARIS, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
-
PARIS, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
-
PARIS, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
-
Combination with checkpoint inhibitors decreased tumor growth rate and prolonged survival in syngeneic HCC mouse model PARIS & COPENHAGEN, Denmark--(BUSINESS...
-
· Clinical development plan in line with objectives · Livatag® on track to deliver its next important milestone with 90% of patients randomized · €12.5m capital increase successfully...
-
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specialized in the development of orphan oncology therapeutics,...
-
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the...
-
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News: Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO): THIS PRESS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN, OR...